Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Wary Of Industry’s New Pre-Market Review Goal Proposals

This article was originally published in The Gray Sheet

Executive Summary

Recent device industry proposals for more aggressive pre-market review goals could result in fewer device clearances and approvals, FDA warns.
Advertisement

Related Content

FDA Embraces Total-Time Pre-Market Review Goals, With Shared Accountability
FDA Embraces Total-Time Pre-Market Review Goals, With Shared Accountability
User Fee Talks On Schedule And Making Progress, Industry Says
Mela Sciences Cites Binding Study Protocol Pact As Key To FDA Reversal On MelaFind PMA
User Fee Talks On Schedule And Making Progress, Industry Says
Mela Sciences Cites Binding Study Protocol Pact As Key To FDA Reversal On MelaFind PMA
Industry Questions On CDRH Reform Plans Hold Up User Fee Progress
Industry Questions On CDRH Reform Plans Hold Up User Fee Progress
User Fee Negotiators Far Apart: Industry Seeks To Delay New Fee Levels Until FDA Improves Performance
Citizen Petition: FDA Reneged On Binding Agreement For Melanoma Device

Topics

Advertisement
UsernamePublicRestriction

Register

MT030498

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel